Skip to main content
OpenTrials
Completed

NCT Number: NCT07565012

Comparative Evaluation of Diclofenac Sodium and Ibuprofen for Post-Endodontic Pain Management

This randomized controlled trial aims to compare the effectiveness of Diclofenac sodium and Ibuprofen in reducing pain after root canal treatment. Post-endodontic pain is a common complication following treatment of irreversible pulpitis and may affect patient comfort and recovery. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to manage postoperative dental pain due to their anti-inflammatory and analgesic properties.

A total of 60 adult participants diagnosed with irreversible pulpitis involving a single first molar will undergo single-visit root canal therapy. Participants will be randomly assigned to receive either diclofenac sodium 50 mg or ibuprofen 400 mg immediately after treatment. Pain levels will be recorded using a Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours following treatment. The use of rescue analgesics will also be documented.

The study aims to determine which medication provides better pain relief and reduces the need for additional analgesics following endodontic treatment. Findings from this study may help guide clinicians in selecting the most effective medication for postoperative pain management in dental practice.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Armed Forces Institute of Dentistry

Rawalpindi, 46000, Pakistan

About this study

Post-endodontic pain is a frequently encountered complication following root canal therapy and may occur due to inflammatory responses caused by mechanical instrumentation, chemical irritation, or microbial factors affecting the periapical tissues. Effective pain management following endodontic procedures is important for improving patient comfort, treatment satisfaction, and recovery.

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for dental pain because they inhibit cyclooxygenase enzymes responsible for prostaglandin synthesis, thereby reducing inflammation and pain. Among NSAIDs, diclofenac sodium and ibuprofen are widely used due to their analgesic and anti-inflammatory properties. However, differences in pharmacological action, tissue penetration, potency, and duration of effect may influence their comparative effectiveness in controlling post-endodontic pain.

This randomized controlled trial will be conducted at the Department of Operative Dentistry, Armed Forces Institute of Dentistry, Rawalpindi, Pakistan. A total of 60 participants aged 18-65 years diagnosed with irreversible pulpitis involving a single maxillary or mandibular first molar will be enrolled. Participants will be randomly allocated into two equal groups. One group will receive diclofenac sodium 50 mg, while the other group will receive ibuprofen 400 mg following completion of single-visit root canal therapy.

Standardized endodontic procedures will be performed by an experienced operator under local anesthesia using 2% lidocaine with epinephrine. Root canal preparation, irrigation, obturation, and temporary restoration will be completed using standardized techniques to minimize procedural variability.

Pain intensity will be assessed using a Visual Analogue Scale (VAS) before treatment and at 6, 12, 24, and 48 hours after treatment. Participants will maintain a pain diary to record pain levels and rescue analgesic intake. Secondary outcomes include the frequency of rescue medication use and monitoring of adverse effects.

Data analysis will be performed using Statistical Package for Social Sciences (SPSS) version 23. Appropriate descriptive and inferential statistical methods will be applied following assessment of data normality. Comparative analysis between treatment groups will evaluate differences in postoperative pain scores and rescue analgesic requirements.

The results of this study may provide evidence regarding the comparative analgesic efficacy of diclofenac sodium and ibuprofen in endodontic pain management. This may support clinicians in selecting optimal postoperative analgesic protocols for patients undergoing root canal treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with Irreversible Pulpitis involving a single maxillary or mandibular first molar Age between 18 and 65 years Patients requiring single-visit root canal treatment Patients able to understand and record pain using Visual Analogue Scale (VAS) Systemically healthy individuals (ASA I-II) Willingness to participate and provide informed consent

Exclusion criteria

Pregnant or lactating women Presence of periapical pathology on radiographic examination Patients with generalized periodontal disease affecting prognosis Use of analgesics or anti-inflammatory drugs within 6 hours prior to treatment Known allergy to Ibuprofen, Diclofenac sodium, or other NSAIDs Patients on medications affecting pain perception (e.g., opioids, antidepressants, anticonvulsants) History of drug abuse or substance dependence Non-vital pulp detected during access opening or instrumentation Inability to complete endodontic treatment in a single visit Failure to achieve proper bleeding response confirming diagnosis of irreversible pulpitis

Treatment and study plan

Ibuprofen

Drug

Participants assigned to this intervention will receive 400 mg oral ibuprofen immediately after completion of single-visit root canal treatment. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) commonly used for postoperative pain management due to its analgesic and anti-inflammatory effects. Pain intensity will be monitored using the Visual Analogue Scale at 6, 12, 24, and 48 hours after treatment.

Other names: Ibuprofen 400 mg

Diclofenac Sodium

Drug

Participants assigned to this intervention will receive 50 mg oral diclofenac sodium immediately after completion of single-visit root canal treatment. Diclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties used for postoperative pain control. Pain intensity will be assessed using the Visual Analogue Scale at 6, 12, 24, and 48 hours following treatment.

Primary outcomes

  1. Postoperative Pain Intensity Following Root Canal Treatment

    Time frame: 6, 12, 24, and 48 hours after completion of root canal treatment

    Postoperative pain intensity will be assessed using a 10-point Visual Analogue Scale (VAS) to compare the analgesic effectiveness of Diclofenac sodium and Ibuprofen following single-visit root canal treatment. Participants will record pain scores at predefined intervals after treatment.

Secondary outcomes

  1. Rescue Analgesic Consumption Following Root Canal Treatment

    Time frame: Within 48 hours after completion of root canal treatment

    The frequency and quantity of rescue analgesic intake will be recorded to evaluate additional pain medication requirements in participants receiving either diclofenac sodium or ibuprofen after endodontic treatment.

Sponsors and collaborators

Lead sponsor

Armed Forces Institute of Dentistry, Pakistan

Other

Registry information

Official study title

Comparative Evaluation of the Efficacy of Diclofenac Sodium and Ibuprofen in the Management of Post-Endodontic Pain Following Single-Visit Root Canal Treatment: A Randomized Controlled Trial

Acronym: DIPI-PEP

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 4, 2026
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.